Treatment of Recurrent
FMT
IBD
Iran
fecal microbiota transplantation
inflammatory bowel disease
rCDI
recurrent Clostridioides difficile infection
Journal
Journal of inflammation research
ISSN: 1178-7031
Titre abrégé: J Inflamm Res
Pays: New Zealand
ID NLM: 101512684
Informations de publication
Date de publication:
2020
2020
Historique:
received:
01
06
2020
accepted:
07
09
2020
entrez:
28
9
2020
pubmed:
29
9
2020
medline:
29
9
2020
Statut:
epublish
Résumé
Fecal microbiota transplantation (FMT) is an effective treatment option for patients with recurrent Eight patients with established IBD (7 with ulcerative colitis and 1 with Crohn's disease) who underwent at least one FMT via colonoscopy for treatment of rCDI were enrolled in this study. Demographics, pre-FMT and post-FMT IBD activity, efficacy for rCDI and adverse events (AEs) were assessed during a 6-month follow-up period. All patients had experienced 3 episodes of rCDI and were refractory to conventional therapies with metronidazole and vancomycin. Primary cure and secondary cure rates were assessed after FMT treatments. A total of 10 FMTs were performed via colonoscopy in 8 patients (6/8; 75% men) with a median age of 35 years (range: 22-60). Two patients received a second FMT. Overall, the primary and secondary cure rates were 75% and 100%, respectively. Two patients developed CPE-producing We demonstrated that FMT appears to be an effective, safe and rational therapeutic alternative for resolution of rCDI in patients with underlying IBD. Furthermore, we suggest implementing the CPE-producing
Identifiants
pubmed: 32982371
doi: 10.2147/JIR.S265520
pii: 265520
pmc: PMC7509309
doi:
Types de publication
Journal Article
Langues
eng
Pagination
563-570Informations de copyright
© 2020 Azimirad et al.
Déclaration de conflit d'intérêts
Prof. Dr. Hidekazu Suzuki reports grants, personal fees from Takeda, personal fees from Astellas, personal fees from AstraZeneca, grants from Daiichi-Sankyo, outside the submitted work. The authors declare that they have no other potential conflicts of interest for this work.
Références
Anaerobe. 2020 Feb;61:102113
pubmed: 31698044
Sci Rep. 2019 May 24;9(1):7792
pubmed: 31127185
Clin Infect Dis. 2018 Mar 19;66(7):e1-e48
pubmed: 29462280
Am J Gastroenterol. 2012 Jul;107(7):1079-87
pubmed: 22450732
Clin Gastroenterol Hepatol. 2016 Oct;14(10):1433-8
pubmed: 26905904
J Clin Gastroenterol. 2016 May-Jun;50(5):403-7
pubmed: 26352106
Clin Infect Dis. 2003 Mar 1;36(5):580-5
pubmed: 12594638
J Crohns Colitis. 2014 Mar;8(3):252-3
pubmed: 24184170
Clin Gastroenterol Hepatol. 2017 Apr;15(4):597-599
pubmed: 27923723
PLoS One. 2016 Jan 20;11(1):e0147210
pubmed: 26789728
Clin Gastroenterol Hepatol. 2019 Jan;17(2):345-352
pubmed: 30268564
J Hosp Infect. 2008 Apr;68(4):308-14
pubmed: 18353491
Am J Gastroenterol. 2013 Apr;108(4):478-98; quiz 499
pubmed: 23439232
Clin Microbiol Infect. 2014 Mar;20 Suppl 2:1-26
pubmed: 24118601
J Crohns Colitis. 2016 Apr;10(4):387-94
pubmed: 26519463
Gastrointest Endosc. 2013 Aug;78(2):240-9
pubmed: 23642791
J Hosp Infect. 2019 Jun;102(2):174-188
pubmed: 30926290
Emerg Microbes Infect. 2020 Dec;9(1):1432-1443
pubmed: 32520657
Clin Infect Dis. 2014 Feb;58(4):541-5
pubmed: 24368622
Curr Opin Pediatr. 2013 Feb;25(1):116-21
pubmed: 23241874
Am J Gastroenterol. 2008 Jun;103(6):1443-50
pubmed: 18513271
PLoS One. 2016 Aug 16;11(8):e0161174
pubmed: 27529553
J Crohns Colitis. 2019 Jul 25;13(7):960-961
pubmed: 30852608
Drug Saf. 2019 Jul;42(7):869-880
pubmed: 30972640
Aliment Pharmacol Ther. 2019 Aug;50(3):240-248
pubmed: 31136009
Therap Adv Gastroenterol. 2019 Apr 10;12:1756284819843002
pubmed: 31007720
Ann Intern Med. 2016 Nov 1;165(9):609-616
pubmed: 27547925
Gastroenterology. 2015 Jul;149(1):223-37
pubmed: 25982290
Curr Res Transl Med. 2020 Aug;68(3):125-130
pubmed: 32414632
Lancet. 2011 Jan 1;377(9759):63-73
pubmed: 21084111
Clin Gastroenterol Hepatol. 2013 Aug;11(8):1036-8
pubmed: 23669309
Am J Gastroenterol. 2019 Mar;114(3):384-413
pubmed: 30840605
Gut Microbes. 2017 May 4;8(3):303-309
pubmed: 28102756
Immunol Rev. 2017 Sep;279(1):70-89
pubmed: 28856738
World J Gastroenterol. 2013 Nov 21;19(43):7577-85
pubmed: 24282348
N Engl J Med. 2013 Jan 31;368(5):407-15
pubmed: 23323867
J Clin Gastroenterol. 2010 Sep;44(8):567-70
pubmed: 20485184
Therap Adv Gastroenterol. 2019 Mar 14;12:1756284819836893
pubmed: 30906424
Am J Gastroenterol. 2013 Aug;108(8):1367
pubmed: 23912408
Front Microbiol. 2018 Apr 10;9:646
pubmed: 29692762
Aliment Pharmacol Ther. 2015 May;41(9):835-43
pubmed: 25728808
Aliment Pharmacol Ther. 2018 Jul;48(2):152-159
pubmed: 29851107
United European Gastroenterol J. 2018 Oct;6(8):1232-1244
pubmed: 30288286
J Clin Gastroenterol. 2012 Feb;46(2):145-9
pubmed: 22157239
Aliment Pharmacol Ther. 2011 Feb;33(4):428-41
pubmed: 21198703
Gastroenterology. 2015 Jul;149(1):102-109.e6
pubmed: 25857665
Genome Biol. 2012 Apr 16;13(9):R79
pubmed: 23013615
Inflamm Bowel Dis. 2016 Oct;22(10):2402-9
pubmed: 27580384
Aliment Pharmacol Ther. 2017 Aug;46(3):213-224
pubmed: 28612983
Clin Microbiol Infect. 2017 May;23(5):337.e1-337.e3
pubmed: 28057560
N Engl J Med. 2014 Aug 14;371(7):668-75
pubmed: 25119613
Am J Gastroenterol. 2018 Apr;113(4):481-517
pubmed: 29610508